Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | ATR | Q13535 | 1/20 | 0.48 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.47 |
| ▸ | PI4KA | P42356 | 1/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.47 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12528608 | 0.85 | L3MBTL1 (0.61) | L3MBTL1MAPTCREBBPALDH1A1PIK3CD | |
| SCHEMBL27662571 | 0.84 | L3MBTL1 (0.47) | L3MBTL1MAPTCREBBPALDH1A1KDM4E | |
| SCHEMBL17809809 | 0.82 | LRRK2 (0.64) | L3MBTL1CREBBPALDH1A1KDM4ELMNA | |
| SCHEMBL12369720 | 0.82 | L3MBTL1 (0.65) | L3MBTL1MAPTALDH1A1KDM4ELMNA | |
| SCHEMBL21451426 | 0.81 | PDK2 (0.51) | L3MBTL1MAPTCREBBPALDH1A1KDM4E | |
| SCHEMBL27682172 | 0.81 | PIK3CD (0.52) | L3MBTL1MAPTCREBBPALDH1A1KDM4E | |
| SCHEMBL17870561 | 0.81 | PIK3CD (0.48) | L3MBTL1MAPTCREBBPALDH1A1KDM4E | |
| SCHEMBL18609309 | 0.81 | PIK3CD (0.48) | L3MBTL1CREBBPACSS2PIK3CDPIK3CA | |
| SCHEMBL1032787 | 0.81 | PIK3CD (0.44) | L3MBTL1MAPTCREBBPALDH1A1KDM4E | |
| SCHEMBL18520179 | 0.81 | PIK3CD (0.55) | L3MBTL1MAPTCREBBPALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024086194-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | Suvalent Therapeutics, Inc. (US) | 2024-04-25 | — | — | WO | disclosed |
| US-20230365582-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY ON PROSTAGLANDIN E2 RECEPTOR AND USES THEREOF | KANAPH THERAPEUTICS INC. (KR) | 2023-11-16 | — | — | US | disclosed |
| US-20220411366-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-29 | — | — | US | disclosed |
| WO-2017020428-A1 | NOVEL COMPOUNDS FOR USE AS JAK INHIBITORS | 南昌弘益科技有限公司 | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411366-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | ITGB1, ITGB2, ITGA2 | L3MBTL1 1336/4885MAPT 4656/4885CREBBP 4518/4885 |
| US-20230365582-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY ON PROSTAGLANDIN E2 RECEPTOR AND USES THEREOF | PTGER1, PTGIR, PTGDR2 | L3MBTL1 4875/4885MAPT 4846/4885CREBBP 1331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.